Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-291
2019-003629-78Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing capivasertib + fulvestrant with placebo + fulvestrant (2 arms). Primary endpoint: Progression-free survival. Started Mar 2020; status: active.
02
Drugs
capivasertibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-003629-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003629-78.